TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03296059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional treatment with RBC transfusion
Description: Besides conventional treatment, neonates is given RBC transfusion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: neonates is treated with conventional treatment.
Study: NCT02446496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefadroxil tablets manufactured by GSK
Description: Cefadroxil tablets manufactured by GSK contains 1 mg of Cefadroxil
Study: NCT01174030

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Vehicle Gel BID
Study: NCT02446496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefadroxil tablets manufactured by GSK
Description: Cefadroxil tablets manufactured by GSK contains 1 mg of Cefadroxil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefadroxil tablets manufactured by NP
Description: Cefadroxil tablets manufactured by NP contains 1 mg of Cefadroxil
Study: NCT00796861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Patients will be given Sunitinib 50 mg orally daily for four weeks, followed by a two week holiday. For patients tolerating treatment, three cycles of treatment will be given (18 weeks total).
Study: NCT01064921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: The first vorinostat dose level is 100mg, and the second dose will be 200mg, third dose will be 300mg. If the first vorinostat dose level is found to be excessively toxic, the patient will be reduced to -1 dosing level then if still too toxic reduced again to dose level -2. Dose escalation of vorinostat will continue in increments of 100 mg (i.e., 200 mg on dosing days, 300 mg on dosing days). Vorinostat will be given 3 consecutive days per week (e.g. Monday, Tuesday, Wednesday).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Standard chemoradiation therapy X 7 weeks (Days 7-56), concurrent with oral Vorinostat given three days per week (Mon, Tues, Wed)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Correlative Studies
Description: Day 35, 2 weeks post radiation therapy completion optional tumor/normal muscosal biopsy and blood draw for correlative studies. At day 153 an optional tumor/normal tissue biopsy and blood draw for correlative studies.
Study: NCT02496884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Description: DS-5565 7.5 mg tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Description: DS-5565 7.5 mg tablet for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet for oral use to match DS-5565 7.5 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet for oral use to match DS-5565 7.5 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet for oral use to match DS-5565 7.5 mg tablet
Study: NCT01312402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical brinzolamide 1% in 5mL ophthalmic medication
Description: 1 drop three times a day in both eyes on days 2,3 and 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in 5 mL dispenser
Description: Placebo ophthalmic solution in 5 mL dispenser; 1 drop three times a day on days 2,3 and 4
Study: NCT03606798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 Home visits made by a psychologist
Description: Patient and caregiver interviews with a psychologist at home
Study: NCT03745703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOCHA
Description: (see above)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOCHA
Description: (see above)
Study: NCT00650533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride Tablets 1 mg
Description: 1mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amaryl® Tablets 1 mg
Description: 1mg, single dose fed
Study: NCT03006666

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW Training
Description: CHWs will be trained in DM concepts, motivational interviewing, brief action planning, and stages of behavior change. CHWs will participate in a 105- hour core competency training. CHWs will conduct mock telephone counseling calls with trained standardized patients to enhance skills, gain feedback and develop confidence in these techniques.~In addition to these training experiences, CHWs will have letter templates, motivational interviewing scripts, and protocols available for patient outreach to standardize and guide patient outreach .~The completion of the CHW training will be followed by a final examination of knowledge and evaluation of trial encounters with mock participants (consisting of research staff and advisory board members).~Individuals who do not pass will receive intensive remediation and be required to repeat the examination.~Community Health Worker Coaching Intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Data Only
Description: The teams randomly allocated will not have access to Community Health Workers.
Study: NCT00040404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-1347 10mg
Description: CEP-1347 10mg, a K252a derivative, retains neuroprotective properties

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP1347 25mg
Description: CEP1347 25mg, a K252a derivative, retains neuroprotective properties

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-1347 50mg
Description: CEP-1347 50mg, a K252a derivative, retains neuroprotective properties

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo capsules matching the CEP-1347 capsules
Study: NCT03574025

Intervention type: OTHER
Intervention: Questionnaire
Description: To telephone the patient/family to look into how the patient is doing, moderate/severe brain damage.
Study: NCT02896231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLB1001
Description: PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
Study: NCT04555746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Four PA experts (researchers (PhD) within the field of PA and health in children, and physical education teachers) in collaboration with two members of the ECEC staff and two members of the municipality health department (paediatric physiotherapists) developed a frame for the intervention based on COP elements to be further developed, concretized and implemented by the staff. The intervention lasted for four months and contained the following components (Table 1): pre-meetings and follow up meetings in each ECEC institution; start up seminar and two follow up courses with all the staff members; ongoing planning and collective reflections practice in the ECEC institutions; Facebook group; and an equipment-package.
Study: NCT02312310

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa Flavanol
Description: 12 weeks administration of cocoa flavanol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa Flavanol
Description: 12 weeks administration of cocoa flavanol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa Flavanol
Description: 12 weeks administration of cocoa flavanol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa Flavanol
Description: 12 weeks administration of cocoa flavanol
Study: NCT04401124

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT01168999

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spinal manipulation
Description: Spinal manipulation commonly used in the treatment of low back pain and known to be effective for some individuals experiencing low back pain
Study: NCT02446496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefadroxil tablets manufactured by NP
Description: Cefadroxil tablets manufactured by NP contains 1 mg of Cefadroxil
Study: NCT00969267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ear-acupuncture A
Description: with needle stimulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stimulation B
Description: with bread stimulation on ear acupuncture point

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: stimulation C
Description: without needle stimulation
Study: NCT01823250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Therapy based on Structural Family Therapy
Description: Once per week family therapy based on Structural Family Therapy. Sees to improve parenting practices, communication, and problem solving skills. It also seeks to increase the attachment/bond between parents and adolescents.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Therapy based on Structural Family Therapy
Description: Once per week family therapy based on Structural Family Therapy. Sees to improve parenting practices, communication, and problem solving skills. It also seeks to increase the attachment/bond between parents and adolescents.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Therapy
Description: Group Therapy is provided once per week and is designed to share information on HIV and STI risk and protection. There are typically 8-10 adolescents in a group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Sessions
Description: Psycho-educational sessions are used to provide didactic in formation to parents alone, adolescents alone, or both together. Content may focus on parenting, drug use risks, depression, HIV/STI risk or other major issues that adolescents and families confront. There are also modules that focus on culture-related stressors and processes that can be provided to families for whom this is a prominent issue.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Adolescent Therapy Sessions
Description: Individual sessions with the adolescent focus on Motivational Interviewing, coaching for family sessions, and monitoring of unhealthy behaviors.
Study: NCT03004417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 6001 Dose1
Description: CHF 6001 plus placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 6001 Dose2
Description: CHF 6001 only (high dose)
Study: NCT01168999

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham spinal manipulation
Description: Sham spinal manipulation intended to mimic the studied spinal manipulation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced sham spinal manipulation
Description: Sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people
Study: NCT01498926

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Single dose containing mannitol as isotonic agent. Administered subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Single dose containing glycerol as isotonic agent. Administered subcutaneously (s.c., under the skin)
Study: NCT03465696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group #2 (Intervention)
Description: Group #2 (Intervention)~Survey 2 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group #3 (Intervention)
Description: Group #3 (Intervention)~Survey 3 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~What do you think would be the best way to describe this to a patient?~1. Stelara® acts in an almost all-natural way to help control psoriasis.~2. Stelara® blocks one of the genetic causes of psoriasis.~3. Stelara® makes psoriasis better by blocking the overactive signal that gets the immune system out of balance~4. Stelara® blocks interleukin-23, an important immune system signaling molecule involved in psoriasis~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)
Study: NCT04364633

Intervention type: OTHER
Intervention: Voice Handicap Questionnaire (VHI)
Description: Voice Handicap Index (VHI) self-questionnaire

Intervention type: OTHER
Intervention: Voice Handicap Questionnaire (VHI)
Description: Voice Handicap Index (VHI) self-questionnaire
Study: NCT03219333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: Intravenous (IV) infusion on days 1, 8 and 15 every 28 days
Study: NCT05165121

Intervention type: DEVICE
Group type: OTHER
Intervention: MDHearing smart hearing aid
Description: air conduction hearing aid with app support

Intervention type: DEVICE
Group type: OTHER
Intervention: MDHearing smart hearing aid
Description: air conduction hearing aid with app support
Study: NCT02851576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infusion of ADV specific T cells
Description: Cell engineering
Study: NCT01963624

Intervention type: DEVICE
Intervention: Ultrasonography
Description: Comparison of B-mode US alone and combined use of elasto-doppler US along with B-mode US.
Study: NCT05734092

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional orthodontic treatment
Description: As for patients in the control group, the strength of the nickel-titanium coil will be adjusted every 4 weeks to the required strength of 40 g on each end until reaching normal coverage.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser
Description: The laser will be applied to the root of each of the upper incisors in 8 points (4 points from the labial and 4 points from the palatine), and the head of the device will be placed from the labial side of the root in the center of each of the apical and middle thirds and the mesial and distal of the cervical third in contact with Oral mucosa perpendicular to the root axis, with the application of the laser beam for (16) seconds at one point, and the laser will be re-applied in the same way from the palatal side of the root. So that it was the total application time is (128) seconds for one tooth.~The laser will be applied on the day the upper incisor intrusion started (T1), then on days (3, 7, and 14) of the first month, and starting from the second month, the laser will be applied every (15) day, in addition to adjusting the force gauge every 4 weeks until the end of intrusion stage (T2) and reaching normal coverage.
Study: NCT00491244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a and ribavirin
Description: Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
Study: NCT00318487

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral sinus augmentation with immediately loaded dental implants
Description: Bilateral sinus augmentation with immediately loaded dental implants will be used.
Study: NCT01126541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Arm A: 1000 mg IV (one infusion) every 2 months \\nArm B: 2 x 1000 mg IV (2 infusions) every 2 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Arm A: 1000 mg IV (one infusion) every 2 months \\nArm B: 2 x 1000 mg IV (2 infusions) every 2 months
Study: NCT02829359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir therapy
Description: Patients in the antiviral group received entecavir begin in the first 3 days before surgery for at lest 1 month.
Study: NCT04578314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relating Therapy
Description: Relating Therapy (RT) is a symptom-specific behaviourally oriented intervention that targets interpersonal relating as a key mechanism associated with auditory hallucination distress. The aim is that patients learn to relate more assertively within the difficult relationships they have with both the auditory hallucinations and other people. The RT will follow a treatment manual consisting of three phases: 1. Socialization to relating therapy and its implications; 2. Exploration of themes within the relational history of the participant and their experience of relationships with AH, and interpersonal relating within the family and social environment (identifying any prominent themes, such as abuse, disempowerment, or rivalry); 3. Exploration and development of assertive approaches to relating to AH and other people.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: TAU will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally. Individual therapies may include CBT or psychodynamic interventions. To amend for the heterogeneity of TAU across centres, the type and extent of any treatment received will be protocolled at T1 and T2.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: TAU will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally. Individual therapies may include CBT or psychodynamic interventions. To amend for the heterogeneity of TAU across centres, the type and extent of any treatment received will be protocolled at T1 and T2.
Study: NCT03654677

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inactivated hepatitis A vaccine
Description: A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix Inj
Description: A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
Study: NCT03160703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), 2.0% abrasive silica
Description: Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica (RDA\~58) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), abrasive silica (3.5%)
Description: Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica (RDA\~77) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.

Intervention type: OTHER
Group type: OTHER
Intervention: Sodium Monofluorophosphate (1000 ppm fluoride ), RDA~80
Description: Participants will apply a full brush head of their dentifrice containing 1000 ppm fluoride as SMFP with moderate abrasivity (RDA\~80) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stannous fluoride (SnF2, 0.454%), RDA~120
Description: Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 with higher abrasivity (RDA\~120) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
Study: NCT03062488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: single modal analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: single modal analgesia
Study: NCT02809976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 1.5% Phosphate Cream
Description: twice daily topical application of Ruxolitinib 1.5% Phosphate Cream beginning at baseline and ending at week 20
Study: NCT04229719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl-5-methoxytryptamine
Description: 1.2 mg of melatonin powder will place in the osteotomy site before the insertion of the implant.
Study: NCT02738021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STRONG
Description: A brief 3-session IPT-based preventive intervention, on maternal and child health outcomes.
Study: NCT03175042

Intervention type: DEVICE
Intervention: Masimo spot hemoglobin non-invasive monitor
Description: This non-invasive monitor measures hemoglobin using LED light technology. We will be using it to determine if it is as accurate as routine CBC in anemic obstetric patients.
Study: NCT01513291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6096
Description: MK-6096, two 5 mg tablets (total 10 mg dose), orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, 2 tablets, orally, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 tablets, orally, once daily
Study: NCT03004417

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo only
Study: NCT00452335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 12 mcg capsule once daily (QD)